Pharmacokinetics and Pharmacodynamic Action of Budesonide after Buccal Administration in Healthy Subjects and Patients with Oral Chronic Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 3, 2009, Pages 336-343

  Dilger, Karin ^a   Halter, Jörg ^b   Bertz, Hartmut ^c   Lopez Lazaro, Luis ^d   Gratwohl, Alois ^b   Finke, Jürgen ^c  

^a Dr Falk Pharma GmbH   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF FREIBURG   (Germany)

^d Swiss Pharma Contract Ltd   (Switzerland)

Author keywords

Allogeneic cell transplantation; Budesonide; Chronic graft versus host disease; Clinical trial; Mouth and oral cavity

Indexed keywords

16ALPHA HYDROXYPREDNISOLONE; BUDESONIDE; CALCINEURIN INHIBITOR; CYTOCHROME P450 3A; GLUCOCORTICOID; HYDROCORTISONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INACTIVATION; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSFORMATION; DRUG UPTAKE; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUTH DISEASE; MOUTHWASH; PATIENT COMPLIANCE; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, BUCCAL; ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; BUDESONIDE; CASE-CONTROL STUDIES; CHRONIC DISEASE; CYTOCHROME P-450 CYP3A; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; HYDROCORTISONE; MALE; MOUTHWASHES; PREDNISOLONE;

EID: 59349115912     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.12.001     Document Type: Article

References (37)

1. Horwitz M.E., and Sullivan K.M. Chronic graft-versus-host disease. Blood Rev 20 (2006) 15-27
2. Copelan E.A. Hematopoietic stem-cell transplantation. N Engl J Med 354 (2006) 1813-1826
3. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 11 (2005) 945-955
4. Gilman A.L., and Serody J. Diagnosis and treatment of chronic graft-versus-host disease. Semin Hematol 43 (2006) 70-80
5. Perez-Simon J.A., Sanchez-Abarca I., Diez-Campelo M., et al. Chronic graft-versus-host disease: pathogenesis and clinical management. Drugs 66 (2006) 1041-1057
6. Fraser C.J., and Scott Baker K. The management and outcome of chronic graft-versus-host disease. Br J Hematol 138 (2007) 131-145
7. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 12 (2006) 375-396
8. Imanguli M.M., Pavletic S.Z., Guadagnini J.P., et al. Chronic graft-versus-host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101 (2006) 175-183
9. Fedorak R.N., and Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev 57 (2005) 303-316
10. Elad S., Or R., Garfunkel A.A., et al. Budesonide: a novel treatment for oral chronic graft versus host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95 (2003) 308-311
11. Sari I., Altuntas F., Kocyigit I., et al. The effect of budesonide mouthwash on oral chronic graft versus host disease. Am J Hematol 82 (2007) 349-356
12. Bar-Meir S., Chowers Y., Lavy A., et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology 115 (1998) 835-840
13. Jonsson G., Astrom A., and Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos 23 (1995) 137-142
14. Guengerich F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39 (1999) 1-17
15. Sarikaya D., Chiba I., Bilgen C., et al. RT-PCR-based cytochrome P450 expression profile of oral tissue samples. J Clin Pharm Ther 32 (2007) 445-448
16. Vondracek M., Xi Z., Larsson P., et al. Cytochrome P450 expression and related metabolism in human buccal mucosa. Carcinogenesis 22 (2001) 481-488
17. Dempsey O.J., Coutie W.J.R., Wilson A.M., et al. Evaluation of buccal component of systemic absorption with inhaled fluticasone propionate. Thorax 54 (1999) 614-617
18. Albert M.H., Becker B., Schuster F.R., et al. Oral graft vs. host disease in children-treatment with topical tacrolimus ointment. Pediatr Transplant 11 (2007) 306-311
19. Conrotto D., Carrozzo M., Ubertalli A.V., et al. Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. Transplantation 82 (2006) 1113-1114
20. Martin P.J., Weisdorf D., Przepiorka D., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant 12 (2006) 491-505
21. Flockhart DA. Drug interactions-cytochrome P450 system. http://medicine.iupui.edu/flockhart/table.htm
22. Schubert M.M., Williams B.E., Lloid M.E., et al. Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer 69 (1992) 2469-2477
23. Dilger K., Denk A., Heeg M.H.J., et al. No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology 41 (2005) 595-602
24. Rowland M., and Tozer T. Clinical Pharmacokinetics. Concepts and Applications. 3rd ed (1995), Williams & Wilkins, Baltimore, MD
25. Note for guidance on the investigation of bioavailability and bioequivalence. http://www.emea.europa.eu/pdfs/human/qwp/140198enfin.pdf
26. U.S. Food and Drug Administration. Guidance for Industry. Drug Interaction Studies- Study Design, Data Analysis, and Implications for Dosing and Labeling. http://www.fda.gov/cder/guidance/index.htm#clinical%20pharmacology
27. Shimada T., Yamazaki H., Mimura M., et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270 (1994) 414-423
28. Xie H.G., Wood A.J.J., Kim R.B., et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5 (2004) 243-272
29. Doherty M.M., and Charman W.N. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?. Clin Pharmacokinet 41 (2002) 235-253
30. Ryrfeldt A., Andersson P., Edsbäcker S., et al. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl 122 (1982) 86-95
31. Atkinson A.J. Drug absorption and bioavailability. In: Atkinson A.J., Abernethy D.R., and Daniels C.E. (Eds). Principles in Clinical Pharmacology. 2nd ed (2007), Elsevier, San Diego, CA 37-49
32. Lee V. Mucosal drug delivery. J Natl Cancer Inst Monogr 29 (2001) 41-44
33. Dilger K., Schwab M., and Fromm M.F. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis 10 (2004) 578-583
34. Zhang Y., and Benet L.Z. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40 (2001) 159-168
35. Lin J.H., and Yamazaki M. Role of P-glycoprotein in pharmacokinetics. Clinical implications. Clin Pharmacokinet 42 (2003) 59-98
36. Meisel P., Giebel J., Kunert-Keil C., et al. MDR1 gene polymorphisms and risk of gingival hyperplasia induced by calcium antagonists. Clin Pharmacol Ther 79 (2006) 62-71
37. Lo Muzio L., Staibano S., Pannone G., et al. The human multidrug resistance gene (MDR-1): immunocytochemical detection of its expression in oral SCC. Anticancer Res 20 (2000) 2891-2898